William Blair analyst Ryan Daniels has reiterated their bullish stance on EVH stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Daniels has given his Buy rating due to a combination of factors including Evolent Health’s solid third-quarter performance and the company’s strategic positioning in the market. Despite a recent pullback in stock price, which has created an attractive valuation, Daniels sees a compelling risk/reward profile.
Furthermore, the company’s focus on value-based specialty care and its large addressable market contribute to a strong growth outlook. While there is some uncertainty regarding 2026 earnings due to pending enrollment trends in ACA and Medicare Advantage, Daniels believes that upcoming clarity on these trends will benefit the stock. Overall, the unique market position and robust growth prospects of Evolent Health support the Buy rating.
In another report released today, Stephens also upgraded the stock to a Buy with a $7.00 price target.